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ARTICLE
Synthesis and evaluation of designed PKC
modulators for enhanced cancer immunotherapy
Clayton Hardman 1, Stephen Ho1, Akira Shimizu 1, Quang Luu-Nguyen 1, Jack L. Sloane 1,
Mohamed S. A. Soliman 2, Matthew D. Marsden 3✉, Jerome A. Zack 2,3✉ & Paul A. Wender1✉
Bryostatin 1 is a marine natural product under investigation for HIV/AIDS eradication, the
treatment of neurological disorders, and enhanced CAR T/NK cell immunotherapy. Despite
its promising activity, bryostatin 1 is neither evolved nor optimized for the treatment of
human disease. Here we report the design, synthesis, and biological evaluation of several
close-in analogs of bryostatin 1. Using a function-oriented synthesis approach, we synthesize
a series of bryostatin analogs designed to maintain affinity for bryostatin’s target protein
kinase C (PKC) while enabling exploration of their divergent biological functions. Our late-
stage diversification strategy provides efficient access to a library of bryostatin analogs,
which per our design retain affinity for PKC but exhibit variable PKC translocation kinetics.
We further demonstrate that select analogs potently increase cell surface expression of
CD22, a promising CAR T cell target for the treatment of leukemias, highlighting the clinical
potential of bryostatin analogs for enhancing targeted immunotherapies.
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Targeted biologics and cell therapies for the treatment ofcancer, including monoclonal antibodies (mAbs)1, antibody-drug conjugates (ADC’s)2, bi- and tri-specific antibodies
(biAbs, triAbs)3, chimeric antigen receptor (CAR) T and NK cell
therapies, and neoantigen-directed cell therapies4–6, are revolutio-
nizing oncology. By targeting tumor-specific cell surface antigens
and neoantigens, these therapies offer distinct advantages over
traditional treatment options as they avoid the systemic toxicity
associated with cytotoxic chemotherapies while efficiently and
selectively clearing malignant cells7,8. Although these cell therapies
rely on vastly different mechanisms of action and leverage different
host biological systems for tumor clearance, each is fundamentally
based on a common requirement, specifically sufficient and sus-
tained target (neo)antigen cell surface expression. Notwithstanding
the clinical promise of these recent advances in immuno-oncology,
tumor escape and acquired resistance driven by decreased surface
expression of target (neo)antigens limit the efficacy, durability and
scope of these approaches. Indeed, poor durability of response and
patient relapse associated with variable and decreased antigen
density have been observed across several indications4,5,9–12. The
identification of adjuvants that enhance and sustain surface
expression of target (neo)antigens could broadly address this pro-
blem and improve the efficacy of these approaches by turning cold
tumors into hot ones13, which could then be more effectively
cleared with targeted biologics and cell therapies thereby potentially
increasing not only the number of patient responders but the
durability of their response.
Protein kinase C (PKC) modulators offer a potentially general
solution to this antigen density and persistence problem. Among
the most studied PKC modulators, plant-derived phorbol esters
(PEs) have long been known to influence antigen expression in a
variety of cell lines14–18. Prompted by such findings and with the
intent to identify simplified PE analogs using a function-oriented
synthesis (FOS) strategy19–21, we reported in 1986 a computer-
based analysis of the pharmacophore of PEs and related PKC
modulating ligands, which led to the first designed PKC mod-
ulator—3-(N-acetylamino)-5-(N-decyl-N-methylamino)-benzyl
alcohol (ADMB)22. In 1992, Leon et al.23 showed that ADMB, like
the PEs, enhanced tumor associated antigen (BCA-225) expres-
sion in breast carcinoma cells but, unlike PEs, it did not induce
shedding of the antigen, highlighting the potential for natural
product-inspired designed analogs to exhibit divergent and
superior biological activity. Significantly, the immunomodulatory
properties of the PEs are not unique to this structural class of PKC
modulators. For example, bryostatin 1, a marine macrolide and
potent PKC modulator24,25, also alters expression of surface
antigens in tumor cell lines, making them more immunogenic and
thus more susceptible to immune or other antigen-targeted
clearance strategies17,26–30. Indeed, several pre-clinical and clinical
studies have reported that bryostatin 1 can alter the immuno-
phenotype and increase the immunogenicity of cancer cells in
acute lymphoblastic leukemia (ALL), chronic lymphocytic leuke-
mia (CLL), and non-Hodgkin’s lymphoma (NHL)17,26–31. These
and related studies by a Spaner–Wender collaboration on CLL
antigen expression and by a Zack–Marsden–Wender collaboration
on CD69 expression in CD4+ T cells, the latter related to HIV
eradication, indicate that PKC modulators can enhance expression
and persistence of certain antigens, potentially enhancing a variety
of (neo)antigen-targeted therapies17,30,32–34.
Among antigen-targeting strategies in clinical evaluation, CAR T
cell therapy has recently emerged as an effective treatment for B-cell
malignancies. Specifically, CAR T cells targeting the B cell-restricted
antigen CD19 (Tisagenlecleucel (Kymriah, Novartis), Axicabtagene
ciloleucel (Yescarta, Gilead)) have produced significant clinical
responses in the treatment of leukemias and lymphomas35. How-
ever, antigen loss has been observed as a primary driver in acquired
resistance and patient relapse4,5,11,35,36. To address this mechanism
of tumor escape, researchers have expanded their target portfolio to
other B cell-restricted antigens, culminating in the recent develop-
ment of an anti-CD22 CAR T cell therapy11. Preliminary data from
a phase I trial for ALL with patients who were naïve or resistant to
CD19-targeted CAR immunotherapy was promising, with ~70% of
patients achieving complete remission for a median duration of
6 months11. However, resistance driven by diminished and variable
levels of CD22 surface expression was observed in a subset of
patients who were unresponsive or relapsed following treatment.
Importantly, bryostatin 1 has been shown to upregulate
CD22 surface expression in ALL, CLL and NHL cells both in vitro
and ex vivo26,28,31,37, and in vivo in human clinical trials27,29. This
suggests that bryostatin 1 and by analogy its analogs could be used
in combination with anti-CD22 CAR T therapy to improve patient
outcomes by ensuring that malignant cells maintain sufficient levels
of CD22 surface expression to be effectively cleared. Indeed,
Ramakrishna et al.31 recently demonstrated that natural bryostatin
1 can improve CD22-targeted CAR T activity in a pre-clinical
model of ALL.
Given the potential of PKC modulators to enhance targeted
therapies, it is especially noteworthy that the vast majority of
research in this area over the past several decades has focused on
only a small number of natural products and more specifically
bryostatin 1. This is especially significant because these agents,
while promising clinical leads, are neither evolved nor optimized
for clinical use. As evident from studies on the taxanes and
avermectins, immediate synthetic precursors and derivatives of
natural products, so called close-in analogs, often provide
superior clinical performance38,39. Indeed, while many drugs are
inspired by natural products, few (ca. 6%), as evident from new
chemical entities reported between 1981 and 2014, are natural
products themselves40. This has increasingly motivated the bio-
inspired and synthesis-informed design of close-in or simplified
structures with distinct or superior function19–21.
Unfortunately, synthetic access to close-in analogs of
bryostatin 1 has been precluded by the limited availability of
natural and synthetic material, which is further exacerbated by
the inherent challenges associated with modifying the exqui-
sitely complex bryostatin scaffold. The original hand collection
of natural bryostatin 1, which provided GMP material for
clinical use, produced only 18 g of material from 14 tons of the
source organism Bugula neritina (0.00014% yield) and that is
now nearly depleted41. Re-collection from this marine source
would raise cost, sustainability and environmental concerns due
to bryostatin’s poor and variable natural availability42. Aqua-
culture and engineered biosynthesis have been explored, but the
former encountered capitalization and yield problems and the
latter difficulties in cultivation of the symbiotic bacterium
necessary for production of bryostatin 143. Recently, we
reported a solution to this supply problem, a scalable synthesis
of bryostatin 1, that has afforded sustainable access to
gram scale quantities of the natural product as needed to
ensure further research and its continued clinical evaluation44.
Additionally as reported herein, our chemical synthesis also
serves as a platform for accessing bryostatin analogs and
the exploration of structure–function relationships, thereby
enabling the design and synthesis of potentially more accessible,
more efficacious and better tolerated bryostatin-inspired leads.
Given that bryostatin 1 is in pre-clinical and clinical studies for
widely varied indications including the treatment of Alzhei-
mer’s disease45–47, eradication of HIV/AIDS48–50, multiple
sclerosis51, Niemann Pick disease52, Fragile X53 and enhanced
immunotherapy17,25,30,31, and given that many of these indi-
cations involve different PKC isoforms, access to varied analogs
avoids a one-size-fits-all single agent approach to varied
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therapeutic indications and offers a more disease specific
optimization opportunity.
Here we report the design, synthesis and evaluation of the
first close-in bryostatin 1 analogs. Our design strategy focuses
on making chemical modifications to the bryostatin scaffold
that would be expected to retain compound affinity to PKC, but
could influence PKC function and downstream signaling out-
comes while also potentially being used as needed to tune
formulation and ADME characteristics. 18 analogs were pre-
pared and their activities were compared with synthetic
bryostatin 1. Based on an FOS strategy, these compounds were
designed to retain the pharmacophoric functionalities proposed
for PKC binding in our original pharmacophore model22,54.
Consistent with that model, most of these close-in analogs
exhibited single-digit nanomolar affinities to representative
PKC isoforms, comparable to bryostatin 122,54. In contrast, we
observe a diverse array of activity profiles in a functional assay
measuring PKC translocation in real time in living cells, sug-
gesting that such modifications can indeed elicit differential
biological functions, irrespective of cell-free binding affinities.
Significantly, we also investigate the ability of these analogs
to increase CD22 surface expression in in vitro models of
ALL and AIDS-related lymphomas in connection with emer-
ging antigen-targeted therapies. We found that several analogs
exhibit activity similar to bryostatin 1, suggesting that these
compounds could serve as more accessible and efficacious, and
potentially better tolerated, adjuvants for cancer immunother-
apy and other therapeutic indications.
Results
Design and synthesis of bryostatin analogs. Our FOS design
strategy for bryostatin analogs was guided by our previously
proposed bryostatin pharmacophore model54 and further sup-
ported by recent molecular dynamics simulations55 and REDOR
NMR structural studies56. PKC is a family of seven homologous
signaling kinases classified as conventional (α, β, γ) or novel (δ, ε,
η, θ) based on their subdomain architectures57. Individual iso-
forms, combinations of isoforms, and mutant isoforms of PKC
are implicated in a number of disease pathologies58,59. PKC
maturation and activation are governed by a sequence of highly
orchestrated phosphorylations, conformational changes, and
ultimately translocation to the plasma membrane where they
effect phosphorylations of numerous downstream signaling
proteins57,60. The hallmark of ligand-induced PKC activation is
formation of a ternary complex between the plasma membrane,
ligand and PKC (Fig. 1b)57,58,60. In this context, the bryostatin
scaffold can be considered as two subunits that have distinct but
interdependent functions. Our computational studies revealed
that hydrogen-bonding functionalities around the C-ring subunit
of the bryostatin scaffold, specifically the C1 carbonyl, C26
hydroxyl and C19 hemiketal, are spatially preorganized by the A
and B rings into a binding conformation that mimics PKC’s
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Fig. 1 FOS design strategy for the synthesis of bryostatin analogs. a Retrosynthetic analysis of the bryostatin scaffold with key pharmacophoric elements
highlighted in blue (C1 carbonyl, C19 hemiketal, C26 alcohol). C13 (red sphere) highlighted as a diversification node for analog synthesis. b Rendering of the
PKC-bryostatin-membrane ternary complex. Bryostatin 1 shown in dark blue. Pharmacophoric elements of the C-ring subunit of the bryostatin scaffold (a)
interact directly with PKC (purple) while the A and B rings are imbedded in the plasma membrane (cyan). Adapted with permission from Yang et al.
(https://pubs.acs.org/doi/full/10.1021/acscentsci.7b00475) and the American Chemical Society (ACS)56. Further permissions related to the material
excerpted should be directed to the ACS. c Representative conformers of the bryostatin scaffold bound to PKC that fit experimentally determined
intramolecular distances determined by REDOR NMR. Adapted with permission from Yang et al. (https://pubs.acs.org/doi/full/10.1021/
acscentsci.7b00475) and the ACS56. Further permissions related to the material excerpted should be directed to the ACS. d Convergent construction of
the bryostatin scaffold from acid 1 and enal 2. C13 functionality (highlighted in red) provides a versatile functionalization node for late-stage diversification,
avoiding interference with the pharmacophoric elements of the C-ring (highlighted in blue, a).
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endogenous ligand, DAG (Fig. 1a)54–56,61. Indeed, seminal studies
by our group showed that modification or deletion of any of the
C1, C26 and C19 functionalities reduced or eliminated PKC
binding while changes in the A- and B-rings generally had little or
no effect on binding, suggesting that changes to these subunits
could be used to change physical properties, biological function
and biodistribution and thereby potentially improve efficacy and
tolerability20,54,61–64. We therefore set out to determine which
changes in close-in analogs would justify future progression of the
better performers to more advanced in vivo studies.
In addition to spatially restricting the pharmacophoric elements
of bryostatin’s C-ring subunit to a productive PKC-binding
conformation, the northern subunit is also thought to influence
translocation efficiency of PKC as well as the depth and orientation
of the ligand-PKC complex in membranes, as suggested by recent
long-timescale (400–500 μs) molecular dynamics simulations55.
Specifically, interaction of oxygenation in the A and B-rings with
water molecules at the membrane–cytosol interface putatively
causes the bryostatin-PKC complex to adopt a shallow, angled
orientation with respect to the membrane (Fig. 1b)55. This unique
orientation of the bryostatin 1-PKC complex was not populated
when other potent PKC ligands such as phorbol dibutyrate (PDBu)
and prostratin were modeled, providing an explanation for their
competitive PKC binding but often contrasting downstream
activities55. In a separate study, a combination of REDOR NMR
and molecular dynamics simulations identified a distribution of
PKC-bound bryostatin conformers (Fig. 1c), a feature that was
unique to the bryostatin scaffold and not observed in a phorbol
ester derivative56. Together, these studies suggest that the multiple
PKC-bound conformers available to the bryostatin scaffold could
generate differential orientations of the activated PKC-ligand
complex and influence PKC’s interactions with downstream effector
proteins, thereby explaining bryostatin’s unique biological activity.
This in turn suggests that modifications to the A and B rings of the
bryostatin scaffold could influence compound function by affecting
the orientation of the active PKC signaling complex. With this
decades-derived guiding framework in mind, we designed a series of
compounds that retain the pharmacophoric elements of the
bryostatin C-ring but incorporate modifications to the bryostatin
B-ring, focusing on C13 as a diversification node. This site was
selected because our computational studies suggest that modifica-
tions at this non-pharmacophoric position would preserve PKC-
binding affinity while enabling exploration of its influence on
compound function (e.g. translocation, activity and tolerability). By
leveraging the unique reactivity at this position found in late-stage
synthetic intermediates we were able to generate a set of close-in
bryostatin analogs with diverse chemical functionality at this
position to explore how various substitution patterns in the B-ring
fragment can affect compound function by influencing membrane
association, trafficking and downstream signaling outcomes.
Recently we reported a scalable, step-economical synthesis of
bryostatin 1, which allows for the convergent assembly of a
diversifiable bryostatin macrocyclic skeleton (exo-olefin 3, Fig. 1d)
from two synthetically accessible building blocks (Fig. 1d)44. This
study provided a synthetic supply (>2 g) of bryostatin 1 that is
required to support synthesis studies. The bryostatin fragments,
carboxylic acid 1 and enal 2, are brought together in a Yamaguchi
esterification that proceeds in 82% yield. Formation of bryosta-
tin’s B-ring and closure of the macrocycle is then accomplished
by employing our previously reported Prins-driven macrocycliza-
tion strategy (Fig. 1d), which generates exo-olefin 3. Drawing on
the richness of alkene and ketone chemistry, exo-olefin 3 can be
selectively modified to directly install new B-ring functionality or
converted into the corresponding ketone via a pi-selective
stoichiometric ozonolysis procedure developed by our group
(Fig. 1d). These two functional groups afford chemical reactivity
that is largely orthogonal to the remaining functionality and
provide starting points for exploring how modifications to
bryostatin’s B-ring can influence PKC function (affinity, translo-
cation, and signaling). Owing to the extremely high cost of
natural bryostatin (ca. $1500/mg), the limited current amount of
synthetic bryostatin and its precursors until a production scale-up
synthesis is completed, and the intrinsic challenges of modifying
such a complex scaffold with limited materials, we intentionally
chose to use chemistries that would carry less risk and thus loss of
precious materials. Furthermore, as we needed to work on multi-
milligram scales (~5–10 mg) to enable compound characteriza-
tion and biological evaluation, we limited our initial focus to the
B-ring as our modeling and prior studies suggested that region
tolerated change.
In our initial exploration of chemical space at C13, we sought
to leverage the differentiated reactivity of the C13 exo-olefin over
other pi-systems to generate a series of close-in structural analogs.
For steric and electronic reasons, the C13 olefin was expected to
be the most reactive of the four pi-systems found in this advanced
intermediate (Fig. 2, olefin 3)44. As previously described, global
deprotection of exo-olefin 3 afforded SUW20044. Gratifyingly, di-
hydroxylation of SUW200 selectively afforded vicinal diol
SUW203 in the presence of the C16/C17 alkene, C20 alkynoate
and C21 enoate. In contrast, and in line with our concerns about
the selectivity of even routine reactions on such a complex
scaffold, epoxidations of the exo-olefin 3 and bryostatin 1 with
DMDO or mCPBA proved challenging. Furthermore, attempts to
reduce the C13 olefin using H2 and catalytic Pd/C were also
difficult to control, often providing mixtures of reduction
products. However, we were able to eventually achieve clean
reduction of the C13 exo-olefin and C20 alkynoate without
reducing either the C21 enoate or the C16/17 olefin by decreasing
reaction time and concentration, generating compound 5, which
was subsequently deprotected to afford SUW226.
We next focused on modification of the C13 ketone 4. This
advanced intermediate served as an ideal diversification node as the
C13 ketone presents chemical reactivity that is orthogonal to the rest
of the functionality found in this series of advanced intermediates
(Fig. 3). To conserve material, we began with the synthesis of a
limited series of C13 alkyl enoates. From ketone 4, we generated
compounds with various ester groups to explore how substituent
size and enoate geometry influence compound function. Ester
derivatives were accessed via a Horner–Wadsworth–Emmons
(HWE) olefination of the densely functionalized ketone 4 using
HWE reagents that were prepared via straightforward coupling of
the desired alcohol to diethyl phosphonoacetic acid. Contrasting the
use of a chiral HWE reagent, which controls double bond geometry
as reported in our synthesis of bryostatin 1, we chose to perform
these reactions using simple, non-stereoselective HWE reagents to
access both the (E) and (Z) isomers of enoate 6. Subsequent global
deprotection and HPLC separation of the enoate diastereomers
afforded the indicated analogs (Fig. 3).
In addition, installation of an alcohol at C13 was expected to
provide a convenient functional handle for the late-stage
diversification through esterification and an opportunity to
explore how C13 hybridization affects function. This was readily
accomplished via borohydride reduction of ketone 4 and
esterification of the resultant alcohol (Fig. 4), giving rise to a
structurally diverse set of compounds, which included the C13
alcohol, aliphatic esters, an indolyl ester, a phenyl carbamate, and
both cationic and anionic moieties.
Biological evaluation of C13-modified bryostatin analogs. With
a panel of compounds bearing diverse functionality at C13, we
began to explore how these modifications affect PKC binding and
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biological function. Because an obvious prerequisite for PKC
pathway involvement is binding to PKC, compounds were initi-
ally evaluated for PKC affinity in a cell-free competitive binding
assay with tritiated phorbol dibutyrate ([3H]-PDBu). Assays were
performed with representative members of both the conventional
(PKCα) and novel (PKCδ) PKC families. Subsequently, com-
pounds were assayed for PKC isoform translocation in real time
in living cells using an optical assay. Translocation to the plasma
membrane is the hallmark of PKC activation18,57,60 and therefore
monitoring the subcellular localization of a PKCδ-GFP fusion
protein via confocal microscopy offers a convenient method for
determining whether a compound enters a cell and engages its
PKC isoform target64. Finally and of clinical significance, we also
determined the effect of compounds on CD22 surface expression
in vitro in NALM6 cells, an ALL cell line previously studied in
connection with CD22-targeted CAR T cell therapy, and two
additional lymphoma cell lines11,31,65. PKC binding, translocation
and CD22 surface expression data are summarized in Fig. 5 and
Table 1.
Our goal was to determine whether PKC affinity and in vitro
PKC activation (measured via intracellular PKC translocation)
correlate, and how binding and translocation influence down-
stream function (CD22 expression). Consistent with our computer
modeling studies, nearly all of the compounds designed using our
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pharmacophore model retained potent PKC-binding affinity (<10
nM), comparable to bryostatin 1 (Table 1). However, certain C13
functionalities decreased PKC affinity due to putative differences
in membrane partitioning or ligand steric effects. For example,
charged substituents at C13 (SUW211, SUW212) decreased
affinity to PKC by ~20-100-fold (Table 1), consistent with the
less effective partitioning of these groups in the phosphatidyl
serine (PS) vesicle complex (membrane surrogate used in the
cell-free binding assay). In addition, substitution of the C13
methyl-(Z)-enoate with a benzyl-(Z)-enoate resulted in a ~30-fold
decrease in affinity, suggesting a size limit to groups at this site.
Similar decreases in binding affinity were not observed in C13
esters with more conformationally flexible linkers bearing large,
relatively hydrophobic substituents (SUW209, SUW210, Table 1).
Aside from these exceptions, the majority of compounds tested
exhibited single-digit nanomolar binding affinities to PKC, further
supporting the predictive value of our proposed pharmacophore
model and prompting the progression of these compounds to
more advanced in vitro PKC translocation assays.
Cell-free ligand binding to PKC is a necessary but not sufficient
prerequisite to elicit function, as a ligand must enter the cell
and engage PKC to form a functional PKC-ligand membrane
complex. Both experimental studies and molecular dynamics
simulations suggest that the PKC-ligand complex can assume
multiple bound states, putatively influencing the differential
association of scaffolding proteins and phosphorylation of down-
stream effector proteins, thereby resulting in diverse biological
outcomes18,55–57,60. Therefore, our next goal was to determine
whether the most potent PKC binders enter cells and show similar
or different dynamic interactions with PKC.
Significantly, our studies show that the thermodynamics of
PKC binding and the kinetics of ligand cell entry and PKC
translocation are often decoupled, a finding that could be
exploited to control isoform-selective signaling. As our positive
comparator, synthetic bryostatin 1, a single-digit nanomolar
binder of all PKC isoforms, translocates ~70% of cytosolic PKCδ-
GFP to the plasma membrane within 5 min at a concentration
of 200 nM (Table 1, Fig. 5). While introducing hydrophilic
substituents at C13 (SUW203, SUW204) generated compounds
that bind both conventional and novel PKC isoforms with
single-digit nanomolar affinity, these analogs exhibited different
behavior than bryostatin 1 in the translocation assay (Fig. 5b, c).
At 200 nM SUW204 translocated only ~25% of cytosolic PKC to
the plasma membrane at 20 min while SUW203 required a
concentration of 1000 nM to translocate ~50% of cytosolic
PKC. Similarly, compounds with charged substituents at C13
(SUW211, SUW212) did not achieve sustained translocation of
PKC at up to 1000 nM (Table 1, Fig. 5d). This suggests that
interaction of the membrane with the functionality on bryosta-
tin’s B-ring is critical for compound function and that PKC
binding is necessary, but not sufficient for compound activity
in vitro. Compounds with hydrophilic or charged modifications
at C13 would putatively inefficiently cross or embed in the plasma
membrane, and thus would exhibit attenuated activity. This
changes how one thinks about PKC modulators from an
emphasis on the thermodynamics of binding to the additional
issue of translocation kinetics.
We also examined a series of C13 esters of different sizes,
hydrophobicities, and varied structural motifs (aryl, heteroaryl,
alkyl, adamantyl), all of which could be efficiently accessed from
the C13 alcohol (Fig. 4). Although we found that diverse
functionality was tolerated at this position with respect to PKC-
binding affinity, our analogs exhibited vastly different transloca-
tion dynamics. In contrast to the free alcohol SUW204, capping
the C13 hydroxyl group with smaller hydrophobic substituents
generated compounds that were comparable to bryostatin 1 at
translocating PKC (Fig. 5d). The two diastereomers of the C13
acetate (SUW206 and SUW207) exhibited almost identical
behavior both to each other and to bryostatin 1. Although C13
phenyl carbamate SUW208 effectively translocated PKC to the
plasma membrane at 200 nM, it exhibited a delayed time course,
requiring ~15 min for translocation, relative to other analogs that
were active in this assay (Fig. 5d), indicating that small changes in
size and/or polarity at this position can influence ligand-mediated
Table 1 Biological evaluation of bryostatin analogs.
Compound Ki PKCα (nM) Ki PKCδ (nM) % Translocation (concentrationa) Fold increase CD22 expressionb
Bryostatin 1 0.8 1.1 70% (200 nM) 2.10
SUW200 4.1 7.6 70% (200 nM) 1.73
SUW201 0.54 1.4 65% (200 nM) 1.59
SUW203 1.0 4.1 50% (1000 nM) 1.16
SUW204 1.4 3.7 25% (200 nM) 0.98
SUW206 1.0 1.3 60% (200 nM) 1.63
SUW207 2.0 5.4 60% (200 nM) 1.33
SUW208 1.0 4.7 75% (200 nM) 1.68
SUW209 1.6 3.5 60% (1000 nM) 1.45
SUW210 5.6 7.3 75% (1000 nM) 1.49
SUW211 98 27 20% (1000 nM) ND
SUW212 40 24 50% (1000 nM)c ND
SUW217 9.2 9.4 75% (200 nM) 1.97
SUW218 7.1 6.6 55% (200 nM) 1.92
SUW219 37 25 60% (1000 nM) ND
SUW220 16 15 50% (1000 nM) ND
SUW226 5.8 6.6 75% (200 nM) 1.76
SUW229 1.8 1.2 50% (200 nM) 2.35
SUW230 4.2 9.4 65% (200 nM) 1.62
Compounds were evaluated for PKC-binding affinity in a competitive binding assay with [3H]-phorbol dibutyrate in PKCα and PKCδ, members of the conventional and novel PKC isoform families,
respectively. Cell entry and PKC activation in living cells was determined by monitoring translocation of a PKCδ-GFP fusion protein from the cytosol to the plasma membrane. Representative images
included in Fig. 5.
ND not determined.
aIndicates minimum effective concentration required to induce translocation of PKC-GFP to the membrane.
bIn NALM6 cells at 1 nM relative to DMSO control (n = 3 biological replicates).
cIndicates only brief translocation observed (Fig. 5d).
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PKC activation and signaling and/or the kinetics and efficacy of
cell entry.
To complement the synthesis of compounds with relatively
similar sized substituents at C13, we also installed larger substituents
with vastly different functionalities than are found in the natural
product. C13 adamantyl ester SUW209 and C13 indoyl ester
SUW210 were designed to enhance potential membrane interac-
tions via increased localized hydrophobicity or to pick up cation-pi
contacts with cationic lipid headgroups on the membrane,
respectively. We found that while both compounds are high affinity
PKC binders (Table 1), they are inactive at 200 nM in the PKC
translocation assay and require 1000 nM to translocate ~70% of
cytosolic PKC to the plasma membrane at ~5min (Fig. 5d).
This finding, made possible by this collection of close-in analogs,
prompted us to examine how C13 functionality can influence bulk
compound properties and the correlation between compound
hydrophobicity (measured using cLogP) and activity (PKC
translocation). Plotting cLogP vs. percentage of membrane asso-
ciated PKCδ-GFP at 200 nM (Supplementary Figure 56) revealed an
effective window of cLogP values required for efficient translocation.
Compounds with cLogP values between 1.0 and 4.0 were active at
200 nM, suggesting that lipophilicity must be effectively balanced to
retain activity. It is also noteworthy that among compounds
within the effective range of lipophilicity, variable dynamics of
PKC activation are observed. Although most compounds exhibit
logarithmic activation curves, select compounds exhibit delayed
activation patterns (SUW208, Fig. 5d), or more sustained linear
activation dynamics (SUW218, SUW229, Fig. 5c). These observa-
tions of the kinetics of PKC-ligand association and intracellular
distribution of the complex can be rationalized by the timing of
ligand entry into the cell and post-entry ligand-controlled partition-
ing of the PKC-ligand complex between the plasma membrane and
cytosol, with more polar compounds having slower entry and a
limited ability to form a stable complex with the plasma membrane.
This is of potential clinical consequence as it is well known that the
dynamics of PKC activation can have profound consequences for
downstream signaling outcomes47,58.
C13 alkyl enoates in both the (Z) and (E) geometries were well
tolerated with the exception of benzyl enoates SUW219 and
SUW220. Interestingly, benzyl enoate SUW219 binds PKC with a
~2-fold decrease in affinity, suggesting that perhaps the (Z) olefin
geometry can position C13 substituents in an orientation that
impacts the conformation of pharmacophoric elements in the C-
ring. In general however, smaller, linear alkyl enoates are potent
binders of PKC and active ligands in vitro (Table 1, Fig. 5c),
although they do affect PKC translocation dynamics.
Having established the potent affinities of members of our
analog library and their PKC translocation kinetics, we next
sought to evaluate our close-in analogs in an assay pertinent to
the clinical use of bryostatin and its analogs as adjuvants to
enhance targeted cancer immunotherapies. Our approach focused
on CD22-targeted CAR T cell therapy, which has been reported
to cure patients with ALL while those who fail this treatment are
thought to have a lower surface density of CD2211,31,65. Fry
et al.65 demonstrated that a critical threshold of CD22 surface
density is required for activation of anti-CD22 CAR T cells
in vitro and tumor clearance in a murine tumor xenograft
model11. More recently, Ramakrishna et al.31 demonstrated that
natural bryostatin 1-promoted increases in CD22 surface expres-
sion can improve the efficacy and durability of CAR T-mediated
tumor clearance in in vivo models of ALL, suggesting that
bryostatin and as yet unexplored analogs could be used to
improve patient outcomes when used in combination with anti-
CD22 CAR T therapy. To investigate synthetic bryostatin 1 and
bryostatin analogs as adjuvant leads for CD22-targeted CAR T
therapy, we developed an in vitro assay for bryostatin-induced
increased CD22 surface expression in ALL using NALM6 cells.
Using this assay, we sought to determine whether synthetic
bryostatin 1 and bryostatin analogs could achieve sufficient
increase in CD22 surface density as required for CD22-targeted
CAR T cell-mediated tumor clearance. NALM6 cells were
incubated with bryostatin 1 and bryostatin analogs for 24 h, at
which point compounds were washed out of the media and cells
were analyzed for CD22 surface expression by flow cytometry.
We found that bryostatin 1 induces a >2-fold increase in
CD22 surface density (Fig. 6). Intriguingly, bryostatin-promoted
increases in CD22 surface expression are sustained for up to
7 days following treatment (Fig. 6a), a finding consistent with
recent work31. This further suggests that sequential administra-
tion of bryostatin 1 or a bryolog to enhance the CD22 target
density followed by an anti-CD22 CAR T cell infusion could be a
viable strategy for clearing CD22lo tumor cells which appear to be
driving patient relapse11.
Importantly, as C13-modified bryostatin analogs displayed a
range of activities in our CD22 induction assay, select compounds
proved highly effective and displayed activities comparable to
bryostatin 1 (Fig. 6b). Surprisingly, we observed a pronounced effect
in C13 enoate geometry on compound function in both the C13
methyl and allyl enoates (Fig. 6b). (Z)-enoates were considerably
more active than the corresponding (E)-enoates, further suggesting
that PKC signaling dynamics can be modulated by modifications to
the B-ring of the bryostatin scaffold. As previously noted, top
performer SUW229 displays a different PKC activation profile
relative to bryostatin 1, suggesting that it is possible that differential
PKC activation dynamics can influence biologically significant
downstream signaling outcomes.
Finally, to determine whether the results observed in NALM6
cells apply to other cell lines, we incubated the AIDS-related
lymphoma cell lines JB and 2F7 cells with synthetic bryostatin 1,
SUW201 and SUW229 (Fig. 6c, d). JB is an Epstein–Barr virus
(EBV)-negative AIDS-lymphoma cell line originally grown out of a
bone marrow sample derived from an HIV+ individual, which
harbors the Burkitt lymphoma translocation66. 2F7 is an AIDS-
associated non-Hodgkin’s lymphoma cell line of the Burkitt subtype,
which is positive for EBV67. Burkitt lymphoma is one of the most
common subtypes of AIDS non-Hodgkin’s lymphoma and along
with Hodgkin’s lymphoma represents a significantly greater risk to
AIDS patients relative to the general population due to their
impaired cellular immunity68. Significantly, synthetic bryostatin 1
and analogs SUW201 and SUW229 upregulated CD22 surface
expression by ~2-fold in each cell line tested (Fig. 6c, d), further
highlighting the potential generality of using PKC modulators for
enhancing CD22-targeted cancer immunotherapies.
Discussion
In summary, we report the design, synthesis and biological eva-
luation of close-in analogs of bryostatin 1, a natural product of
current clinical interest. Our step economical and scalable access
to the bryostatin scaffold has provided sufficient material to
enable a late-stage diversification strategy, leading to the next
generation of bryostatin-derived lead compounds and high-
lighting the importance of chemical synthesis in natural product-
inspired drug discovery. Using an FOS strategy, we designed and
prepared a set of structurally diverse analogs and evaluated how
variations in their structures influence their binding to PKC, their
in vitro translocation of a PKC fusion protein, and their
enhancement of CD22 antigen density in in vitro models of ALL
and AIDS-related NHL. Significantly, while almost all analogs
show bryostatin-like affinity to PKC in accord with our phar-
macophore model, several exhibit notably different PKC isoform
translocation kinetics and thus serve as potential leads for
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isoform-selective PKC modulation connected to different clinical
indications and for the identification of potentially better toler-
ated leads. Of further potential clinical significance, these syn-
thetic studies have enabled access to a class of promising leads for
enhancing antigen-targeted immunotherapy, including enhanced
CD22-targeted CAR T therapy. Given the towering importance of
natural product-inspired analogs in human therapy, these com-
pounds can serve as leads for further therapeutic studies across
numerous indications that have thus far focused for decades
principally on bryostatin 1 alone. More generally, this FOS
approach calls attention to the use of nature’s treasure trove of
natural products to inspire the design of potentially superior,
better tolerated and synthetically more accessible agents for the
prevention, diagnosis and treatment of disease.
Methods
Synthesis of bryostatin analogs. Experimental details for the synthesis of all
previously unreported compounds, including experimental procedures, character-
ization and spectral data are provided in the Supplementary Information (Sup-
plementary Methods).
Biological evaluation of bryostatin analogs. Assay protocols for the PKC
competitive binding assay, PKC-GFP translocation assay and CD22 expression
assays are also provided in the Supplementary Information (Supplementary
Methods).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data supporting the findings of this study are available within the Article and its
Supplementary Information, or from the corresponding author upon request. Raw data
associated with Figs. 5 and 6 are also available upon request.
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